ICON Public Limited Company
ICLR
Rank in Stocks
#1650
ICON Public Limited Company, a clinical research organization, provides... ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Share Price
$167.98
Last synced: 2026-10-19
Market Cap
$12.96B
Change (1 day)
-1.29%
Change (1 year)
-10.86%
Country
IE
Trade ICON Public Limited Company (ICLR)
Category
Healthcare
P/E ratio for ICON Public Limited Company (ICLR)
P/E ratio as of October 2026 TTM: 39.38
According to ICON Public Limited Company latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 39.38. At the end of 2023 the company had a P/E ratio of 37.95.
P/E ratio history for ICON Public Limited Company from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 39.38 | 80.24% |
| 2024 | 21.85 | -42.42% |
| 2023 | 37.95 | 21.09% |
| 2022 | 31.34 | -76.90% |
| 2021 | 135.68 | 331.54% |
| 2020 | 31.44 | 26.76% |
| 2019 | 24.80 | 14.51% |
| 2018 | 21.66 | -1.60% |
| 2017 | 22.01 | 38.92% |
| 2016 | 15.85 | -16.84% |
| 2015 | 19.06 | 4.81% |
| 2014 | 18.18 | -24.06% |
| 2013 | 23.94 | -20.29% |
| 2012 | 30.04 | -33.47% |
| 2011 | 45.15 | 200.61% |
| 2010 | 15.02 | 11.16% |
| 2009 | 13.51 | -7.96% |
| 2008 | 14.68 | -7.47% |
| 2007 | 15.87 | 13.86% |
| 2006 | 13.93 | -38.57% |
| 2005 | 22.68 | 356.33% |
| 2004 | 4.97 | 12.27% |
| 2003 | 4.43 | -18.73% |
| 2002 | 5.45 | -20.05% |
| 2001 | 6.81 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -8.20% |
US
|
|
| 39.77 | 0.99% |
US
|
|
| -290.26 | -837.01% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -13.20% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.